Free Trial

Ovid Therapeutics (OVID) Stock Price, News & Analysis

-0.01 (-0.33%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
113,606 shs
Average Volume
117,537 shs
Market Capitalization
$212.82 million
P/E Ratio
Dividend Yield
Price Target

Ovid Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
169.4% Upside
$8.08 Price Target
Short Interest
4.81% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.19mentions of Ovid Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$50,364 Bought Last Quarter
Proj. Earnings Growth
From ($0.85) to ($0.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.15 out of 5 stars

Medical Sector

183rd out of 923 stocks

Pharmaceutical Preparations Industry

70th out of 429 stocks

OVID stock logo

About Ovid Therapeutics Stock (NASDAQ:OVID)

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

OVID Stock Price History

OVID Stock News Headlines

TD Cowen Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)
5 Oversold Biotech Stocks To Buy Right Now
See More Headlines
Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.10 per share


Free Float
Market Cap
$212.82 million

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Jeremy Max Levin Ba Zoology (Age 71)
    Dphil, Mb Bchir, President, CEO & Chairman
    Comp: $1.03M
  • Mr. Jeffrey A. Rona (Age 56)
    Chief Business and Financial Officer
    Comp: $761.24k
  • Mr. Thomas Michael Perone J.D. (Age 59)
    M.B.A., General Counsel, Chief Compliance Officer & Corporate Secretary
    Comp: $745.71k
  • Mr. Jason Tardio M.B.A. (Age 47)
    Chief Operating Officer
    Comp: $652.84k
  • Mr. Simon D. Kelner (Age 50)
    Chief Human Resources Officer
  • Dr. Dirk Haasner (Age 59)
    Senior Vice President of Global Manufacturing & CMC QA
    Comp: $416.95k
  • Dr. Todd F. Baumgartner M.D.
    M.P.H., Senior Vice President of Regulatory Affairs
  • Dr. Julia Tsai Ph.D. (Age 49)
    Senior Vice President of Clinical Development
  • Ms. Meg Alexander
    Chief Strategy Officer
  • Dr. Manoj Malhotra M.D.
    Chief Medical Officer

OVID Stock Analysis - Frequently Asked Questions

Should I buy or sell Ovid Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OVID shares.
View OVID analyst ratings
or view top-rated stocks.

What is Ovid Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued 1-year price targets for Ovid Therapeutics' shares. Their OVID share price targets range from $3.50 to $11.00. On average, they predict the company's stock price to reach $8.08 in the next year. This suggests a possible upside of 169.4% from the stock's current price.
View analysts price targets for OVID
or view top-rated stocks among Wall Street analysts.

How have OVID shares performed in 2024?

Ovid Therapeutics' stock was trading at $3.22 on January 1st, 2024. Since then, OVID shares have decreased by 6.8% and is now trading at $3.00.
View the best growth stocks for 2024 here

When is Ovid Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 2nd 2024.
View our OVID earnings forecast

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) posted its quarterly earnings data on Friday, March, 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.05. The firm had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.10 million. Ovid Therapeutics had a negative net margin of 10,691.14% and a negative trailing twelve-month return on equity of 53.62%.

What other stocks do shareholders of Ovid Therapeutics own?
When did Ovid Therapeutics IPO?

Ovid Therapeutics (OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (5.44%), Vanguard Group Inc. (4.20%), Empowered Funds LLC (0.18%), Assenagon Asset Management S.A. (0.16%), SG Americas Securities LLC (0.05%) and BNP Paribas Financial Markets (0.05%). Insiders that own company stock include Amit Rakhit, Jason Tardio and Jeremy M Levin.
View institutional ownership trends

How do I buy shares of Ovid Therapeutics?

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OVID) was last updated on 5/26/2024 by Staff

From Our Partners